Brain glucagon-like peptide 1 signaling controls the onset of high-fat diet-induced insulin resistance and reduces energy expenditure

Endocrinology. 2008 Oct;149(10):4768-77. doi: 10.1210/en.2008-0180. Epub 2008 Jun 12.

Abstract

Glucagon-like peptide-1 (GLP-1) is a peptide released by the intestine and the brain. We previously demonstrated that brain GLP-1 increases glucose-dependent hyperinsulinemia and insulin resistance. These two features are major characteristics of the onset of type 2 diabetes. Therefore, we investigated whether blocking brain GLP-1 signaling would prevent high-fat diet (HFD)-induced diabetes in the mouse. Our data show that a 1-month chronic blockage of brain GLP-1 signaling by exendin-9 (Ex9), totally prevented hyperinsulinemia and insulin resistance in HFD mice. Furthermore, food intake was dramatically increased, but body weight gain was unchanged, showing that brain GLP-1 controlled energy expenditure. Thermogenesis, glucose utilization, oxygen consumption, carbon dioxide production, muscle glycolytic respiratory index, UCP2 expression in muscle, and basal ambulatory activity were all increased by the exendin-9 treatment. Thus, we have demonstrated that in response to a HFD, brain GLP-1 signaling induces hyperinsulinemia and insulin resistance and decreases energy expenditure by reducing metabolic thermogenesis and ambulatory activity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Blood Glucose / metabolism
  • Body Temperature Regulation / drug effects
  • Body Temperature Regulation / physiology
  • Brain Stem / physiology
  • Carbon Dioxide / metabolism
  • Diabetes Mellitus, Type 2 / drug therapy
  • Diabetes Mellitus, Type 2 / metabolism*
  • Dietary Fats / pharmacology*
  • Energy Metabolism / drug effects
  • Energy Metabolism / physiology
  • Glucagon-Like Peptide 1 / metabolism*
  • Glucose Intolerance / drug therapy
  • Glucose Intolerance / metabolism
  • Hyperinsulinism / drug therapy
  • Hyperinsulinism / metabolism
  • Insulin Resistance / physiology*
  • Ion Channels / metabolism
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mitochondrial Proteins / metabolism
  • Motor Activity / drug effects
  • Motor Activity / physiology
  • Muscle, Skeletal / metabolism
  • Nitric Oxide Synthase Type II / genetics
  • Nitric Oxide Synthase Type III
  • Oxygen Consumption / drug effects
  • Oxygen Consumption / physiology
  • Peptide Fragments / pharmacology
  • Physical Endurance / drug effects
  • Physical Endurance / physiology
  • Proglucagon / genetics
  • RNA, Messenger / metabolism
  • Signal Transduction / drug effects
  • Signal Transduction / physiology*
  • Uncoupling Protein 2

Substances

  • Blood Glucose
  • Dietary Fats
  • Ion Channels
  • Mitochondrial Proteins
  • Peptide Fragments
  • RNA, Messenger
  • Ucp2 protein, mouse
  • Uncoupling Protein 2
  • Carbon Dioxide
  • exendin (9-39)
  • Proglucagon
  • Glucagon-Like Peptide 1
  • Nitric Oxide Synthase Type II
  • Nitric Oxide Synthase Type III
  • Nos3 protein, mouse